Resumen

HERNANDEZ-BELLO, Jorge et al. Combinations of autoantibodies and their association with clinical variables in rheumatoid arthritis. Acta bioquím. clín. latinoam. [online]. 2018, vol.52, n.1, pp.49-60. ISSN 0325-2957.

In this paper it was evaluated the clinical relevance of analyzing together two new autoantibodies (anti-mutated citrullinated vimentin: anti-MCV and anti-peptidyl arginine deiminase type 4: anti-PAD4) and those used classically in the diagnosis (rheumatoid factor: RF and antibodies against cyclic citrullinated peptide: anti-CCP) of rheumatoid arthritis (RA). The autoantibodies were examined by immunoenzymatic assays in sera of 370 patients with RA and 200 controls. It was observed that anti-MCV antibodies have the highest level of specificity of all the analyzed (100%), while the anti-PAD4 antibodies have the lowest sensitivity (24%) and specificity (95%). Four percent of the individuals that were seronegative for RF and anti-CCP were seropositive for anti-MCV or PAD4. Triple seropositive patients (RF, anti-CCP, and anti-MCV) have greater systemic/ joint inflammation and clinical activity than those with other combinations of autoantibodies (p<0.001). Patients who are only positive for FR had less inflammation and clinical activity (p<0.001). In conclusion, the inclusion of anti-MCV antibodies into the panel used for the diagnosis of RA (RF and anti-CCP) could improve the early diagnosis of individuals, mainly in patients that were seronegative for RF and anti-CCP. On the other hand, there are profiles of autoantibodies associated with the clinical activity of RA patients.

Palabras clave : Autoantibody profiles; Rheumatoid arthritis; Rheumatoid factor; Antibodies against citrullinated proteins; Peptidyl arginine deaminase type 4; Antibodies against mutated citrullinated vimentin.

        · resumen en Español | Portugués     · texto en Español     · Español ( pdf )